Physiologically based pharmacokinetic combined BTK occupancy modeling for optimal dosing regimen prediction of acalabrutinib in patients alone, with different CYP3A4 variants, co-administered with CYP3A4 modulators and with hepatic impairment.

Purpose: To develop a mathematical model combined between physiologically based pharmacokinetic and BTK occupancy (PBPK-BO) to simultaneously predict pharmacokinetic (PK) and pharmacodynamic (PD) changes of acalabrutinib (ACA) and active metabolite ACP-5862 in healthy humans as well as PD in patient...

Full description

Bibliographic Details
Published in:European Journal of Clinical Pharmacology Vol. 78; no. 9; pp. 1435 - 1447
Main Authors: Xu, Lifang, Yu, Shuang, Liu, Huining, Yi, Bowen, Wang, Guopeng, Liu, Yang
Format: equations & formulas research tables/charts Journal Article
Published: Springer Nature Sep2022
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=158447227&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 158447227
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00316970
        NP9
      jtl: European Journal of Clinical Pharmacology
      issn: 00316970
      maglogo: N
    pubinfo:
      dt: Sep2022
      vid: 78
      iid: 9
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        158447227
        157344966
        158447227
        158447227
        10.1007/s00228-022-03338-7
        158447227
      ppf: 1435
      ppct: 12
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Physiologically based pharmacokinetic combined BTK occupancy modeling for optimal dosing regimen prediction of acalabrutinib in patients alone, with different CYP3A4 variants, co-administered with CYP3A4 modulators and with hepatic impairment.
      aug:
        au:
          Xu, Lifang
          Yu, Shuang
          Liu, Huining
          Yi, Bowen
          Wang, Guopeng
          Liu, Yang
        affil: Affiliated Hospital of Jiangxi University of Chinese Medicine, Jiangxi Province, 330006, Nanchang, China
      sug:
        subj:
          Liver Diseases Drug Therapy
          Tyrosine Kinase Inhibitors Pharmacodynamics
          Tyrosine Kinase Inhibitors Pharmacokinetics
          Treatment Outcomes
          Tyrosine Kinase Inhibitors Administration and Dosage
          Oxidoreductases Administration and Dosage
          Drug Therapy, Combination
          Human
          Erythromycin
          Clarithromycin
          Itraconazole
          Simulations
          Biochemical Phenomena
      ab: Purpose: To develop a mathematical model combined between physiologically based pharmacokinetic and BTK occupancy (PBPK-BO) to simultaneously predict pharmacokinetic (PK) and pharmacodynamic (PD) changes of acalabrutinib (ACA) and active metabolite ACP-5862 in healthy humans as well as PD in patients. Next, to use the PBPK-BO to determine the optimal dosing regimens in patients alone, with different CYP3A4 variants, when co-administration with four CYP3A4 modulators and in patients with hepatic impairment, respectively. Methods: The PBPK-BO model was built using physicochemical and biochemical properties of ACA and ACP-5862 and then verified by observed PK and PD data from healthy humans and patients. Finally, the model was applied to determine optimal dosing regimens in various clinical situations. Results: The simulations demonstrated that 100 mg ACA twice daily (BID) was the optimal dosing regimen in patients alone. Additionally, dosage regimens might be reduced to 50 mg BID in patients with five CYP3A4 variants. Moreover, the dosing regimen should be modified to 100 mg (even to 50 mg) once daily (QD) when co-administration with erythromycin or clarithromycin, and be increased to 200 mg BID with rifampicin, and but be avoided co-administration with itraconazole. Furthermore, dosage regimen simulations showed that optimal dosing might be decreased to 50 mg BID in patients with mild and moderate hepatic impairment, and be avoided taking ACA in severely hepatically impaired patients. Conclusion: This PBPK-BO model can predict PK and PD in healthy humans and patients and also predict the optimal dosing regimens in various clinical situations.
      pubtype: Academic Journal
      doctype:
        equations & formulas
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N